GSK’s (GSK) “Buy” Rating Reaffirmed at Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a report released on Thursday, Digital Look reports. They presently have a GBX 2,100 ($26.64) price objective on the stock. Jefferies Financial Group’s price objective points to a potential upside of 38.34% from the company’s current price.

A number of other research analysts also recently issued reports on GSK. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. Citigroup reaffirmed a “buy” rating and set a GBX 2,100 ($26.64) price target on shares of GSK in a research report on Monday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 ($24.74) price target on shares of GSK in a research note on Tuesday, June 18th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, June 18th. Finally, Barclays reiterated an “equal weight” rating and set a GBX 1,725 ($21.88) target price on shares of GSK in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,791.25 ($22.72).

GSK Price Performance

GSK stock opened at GBX 1,518 ($19.26) on Thursday. GSK has a 52 week low of GBX 1,302.60 ($16.52) and a 52 week high of GBX 1,823.50 ($23.13). The company’s 50 day moving average price is GBX 1,688.19 and its two-hundred day moving average price is GBX 1,630.16. The stock has a market cap of £61.93 billion, a P/E ratio of 1,393.52, a P/E/G ratio of 1.19 and a beta of 0.27. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34.

Insider Activity at GSK

In other news, insider Wendy Becker purchased 446 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.47) per share, with a total value of £7,198.44 ($9,131.60). 1.60% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.